ArticleFrontiers in genetics2026
Achieving bottom-up ethical, legal, and societal implications and responsible research and innovation in the synthetic biology research community from the Japanese context.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Confusion, communication, and consent: ELSI barriers to genomics-enhanced remediation in Alberta's oil sands.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomanufacturing and synthetic biology are increasingly seen as essential to realizing a global bioeconomy. Within the broader trends in science and technology policy, the emphasis on foresight and addressing societal challenges has been growing. Addressing ethical, legal, and social implications/issues (ELSI) has become a prerequisite for responding to these trends in several countries, including Japan. This paper focuses on a specific aspect of ELSI, rulemaking, which is attracting increasing attention in the policy context. It highlights the lack of sufficient bottom-up initiatives from the academic research and development (R&D) community in this area and identifies three key areas for action that should be considered: (1) Advancing R&D informed by technological trends as well as policy and societal developments, (2) engaging in proactive deliberation to ensure safety and security, and (3) contributing to discussions on standardization. Moving forward, these recommendations must be elaborated on through discussions with universities, academic societies, the government, funding agencies, industries, and other stakeholders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.